WO2002016413A3 - Cripto tumour polypeptide - Google Patents

Cripto tumour polypeptide Download PDF

Info

Publication number
WO2002016413A3
WO2002016413A3 PCT/EP2001/009646 EP0109646W WO0216413A3 WO 2002016413 A3 WO2002016413 A3 WO 2002016413A3 EP 0109646 W EP0109646 W EP 0109646W WO 0216413 A3 WO0216413 A3 WO 0216413A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
cripto
compositions
colorectal
colon
Prior art date
Application number
PCT/EP2001/009646
Other languages
French (fr)
Other versions
WO2002016413A2 (en
WO2002016413A8 (en
Inventor
Jean-Pol Cassart
Thierry Coche
Remi M Palmantier
Y De Bassols Carlota Vinals
Original Assignee
Smithkline Beecham Biolog
Jean-Pol Cassart
Thierry Coche
Remi M Palmantier
Y De Bassols Carlota Vinals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002420087A priority Critical patent/CA2420087A1/en
Priority to EP01976131A priority patent/EP1311678A2/en
Application filed by Smithkline Beecham Biolog, Jean-Pol Cassart, Thierry Coche, Remi M Palmantier, Y De Bassols Carlota Vinals filed Critical Smithkline Beecham Biolog
Priority to PL01363005A priority patent/PL363005A1/en
Priority to HU0302824A priority patent/HUP0302824A2/en
Priority to KR10-2003-7002701A priority patent/KR20030045041A/en
Priority to JP2002521508A priority patent/JP2004506441A/en
Priority to BR0113491-4A priority patent/BR0113491A/en
Priority to US10/362,597 priority patent/US7439320B2/en
Priority to NZ524344A priority patent/NZ524344A/en
Priority to AU2001295498A priority patent/AU2001295498A1/en
Priority to MXPA03001634A priority patent/MXPA03001634A/en
Publication of WO2002016413A2 publication Critical patent/WO2002016413A2/en
Publication of WO2002016413A3 publication Critical patent/WO2002016413A3/en
Publication of WO2002016413A8 publication Critical patent/WO2002016413A8/en
Priority to NO20030823A priority patent/NO20030823L/en
Priority to US10/407,481 priority patent/US20040138112A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Compositions and methods for the therapy and diagnosis of cancer, particularly lung, colon, colorectal and breast cancer, are disclosed. Illustrative compositions comprise one or more Cripto tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung, colon, colorectal and breast cancer.
PCT/EP2001/009646 2000-08-24 2001-08-20 Cripto tumour polypeptide WO2002016413A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
NZ524344A NZ524344A (en) 2000-08-24 2001-08-20 Immunogenic fragments of the Cripto polypeptide and vaccines and antibodies for treatment of tumors and cancer
US10/362,597 US7439320B2 (en) 2000-08-24 2001-08-20 Cripto tumour polypeptide
PL01363005A PL363005A1 (en) 2000-08-24 2001-08-20 Cripto tumour polypeptide
EP01976131A EP1311678A2 (en) 2000-08-24 2001-08-20 Cripto tumour polypeptide
KR10-2003-7002701A KR20030045041A (en) 2000-08-24 2001-08-20 Cripto tumour polypeptide
JP2002521508A JP2004506441A (en) 2000-08-24 2001-08-20 vaccine
AU2001295498A AU2001295498A1 (en) 2000-08-24 2001-08-20 Cripto tumour polypeptide
CA002420087A CA2420087A1 (en) 2000-08-24 2001-08-20 Cripto tumour polypeptide
HU0302824A HUP0302824A2 (en) 2000-08-24 2001-08-20 Vaccine compositions
BR0113491-4A BR0113491A (en) 2000-08-24 2001-08-20 Isolated polynucleotide and polypeptide, expression vector, host cell, fusion protein, methods for stimulating and / or expanding tumor protein-specific T cells to stimulate an immune response in a patient, to treat cancer in a patient and to inhibit cancer development in a patient, isolated t-cell population, composition, and use of a component.
MXPA03001634A MXPA03001634A (en) 2000-08-24 2001-08-20 Vaccines.
NO20030823A NO20030823L (en) 2000-08-24 2003-02-21 vaccinations
US10/407,481 US20040138112A1 (en) 2000-08-24 2003-04-04 Vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0020953.6 2000-08-24
GBGB0020953.6A GB0020953D0 (en) 2000-08-24 2000-08-24 Vaccine

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/362,597 A-371-Of-International US7439320B2 (en) 2000-08-24 2001-08-20 Cripto tumour polypeptide
US10/407,481 Continuation-In-Part US20040138112A1 (en) 2000-08-24 2003-04-04 Vaccines

Publications (3)

Publication Number Publication Date
WO2002016413A2 WO2002016413A2 (en) 2002-02-28
WO2002016413A3 true WO2002016413A3 (en) 2002-12-05
WO2002016413A8 WO2002016413A8 (en) 2003-02-06

Family

ID=9898284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/009646 WO2002016413A2 (en) 2000-08-24 2001-08-20 Cripto tumour polypeptide

Country Status (19)

Country Link
US (2) US7439320B2 (en)
EP (1) EP1311678A2 (en)
JP (1) JP2004506441A (en)
KR (1) KR20030045041A (en)
CN (1) CN1471579A (en)
AR (1) AR032173A1 (en)
AU (1) AU2001295498A1 (en)
BR (1) BR0113491A (en)
CA (1) CA2420087A1 (en)
CZ (1) CZ2003537A3 (en)
GB (1) GB0020953D0 (en)
HU (1) HUP0302824A2 (en)
IL (1) IL154533A0 (en)
MX (1) MXPA03001634A (en)
NO (1) NO20030823L (en)
NZ (1) NZ524344A (en)
PL (1) PL363005A1 (en)
WO (1) WO2002016413A2 (en)
ZA (1) ZA200301436B (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
EA007469B1 (en) 2001-04-26 2006-10-27 Байоджен Айдек Эмэй Инк. Cripto blocking antibodies and uses thereof
US20060194265A1 (en) * 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
EP1494693B1 (en) * 2002-03-22 2010-12-08 Biogen Idec MA Inc. Cripto-specific antibodies
JP5068072B2 (en) 2003-06-27 2012-11-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド Modified binding molecule comprising a linking peptide
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
BRPI0510883B8 (en) 2004-06-01 2021-05-25 Genentech Inc drug-antibody conjugate compound, pharmaceutical composition, method of manufacturing a drug-antibody conjugate compound, and uses of a formulation, a drug-antibody conjugate and a chemotherapeutic agent, and a combination
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
RU2412947C2 (en) 2004-09-23 2011-02-27 Дженентек, Инк. Antibodies, constructed on cysteine basis and their conjugates
KR20070100346A (en) 2005-01-05 2007-10-10 바이오겐 아이덱 엠에이 인코포레이티드 Cripto binding molecules
US8527510B2 (en) 2005-05-23 2013-09-03 Monster Worldwide, Inc. Intelligent job matching system and method
US8195657B1 (en) 2006-01-09 2012-06-05 Monster Worldwide, Inc. Apparatuses, systems and methods for data entry correlation
US8600931B1 (en) 2006-03-31 2013-12-03 Monster Worldwide, Inc. Apparatuses, methods and systems for automated online data submission
CN101479391A (en) * 2006-04-28 2009-07-08 比奥根艾迪克Ma公司 Composition and methods for the detection of CRIPTO-3
WO2008040759A1 (en) * 2006-10-03 2008-04-10 Pharmexa A/S Method for down-regulation of cripto
US8645817B1 (en) 2006-12-29 2014-02-04 Monster Worldwide, Inc. Apparatuses, methods and systems for enhanced posted listing generation and distribution management
US9779390B1 (en) 2008-04-21 2017-10-03 Monster Worldwide, Inc. Apparatuses, methods and systems for advancement path benchmarking
IN2012DN03025A (en) 2009-09-09 2015-07-31 Ct Se Llc
TWI540136B (en) 2010-04-15 2016-07-01 梅迪繆思有限公司 Pyrrolobenzodiazepines and conjugates thereof
SG185428A1 (en) 2010-06-08 2012-12-28 Genentech Inc Cysteine engineered antibodies and conjugates
JP5889912B2 (en) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド Alaninyl maytansinol antibody conjugate
JP5987053B2 (en) 2011-05-12 2016-09-06 ジェネンテック， インコーポレイテッド Multiple reaction monitoring LC-MS / MS method for detecting therapeutic antibodies in animal samples using framework signature peptides
CN103987407B (en) 2011-10-14 2016-08-24 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and conjugate thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AU2013328628B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
DK2906296T3 (en) 2012-10-12 2018-05-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
SI2906253T1 (en) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
ES2680153T3 (en) 2012-10-12 2018-09-04 Adc Therapeutics Sa Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
RS58921B1 (en) 2012-10-12 2019-08-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP2935273A1 (en) 2012-12-21 2015-10-28 MedImmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EA027910B1 (en) 2013-03-13 2017-09-29 Медимьюн Лимитед Pyrrolobenzodiazepines and conjugates thereof
KR102066318B1 (en) 2013-03-13 2020-01-14 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
MX362970B (en) 2013-03-13 2019-02-28 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof.
WO2015023355A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
CR20160271A (en) 2013-12-16 2016-12-02 Genentech Inc PEPTIDOMETIC COMPOUNDS AND THEIR ANTIBODY-DRUG CONJUGATES
CA2929565A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015095223A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN106714844B (en) 2014-09-12 2022-08-05 基因泰克公司 Anthracycline disulfide intermediates, antibody-drug conjugates and methods
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
JP2017533887A (en) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド Pyrrolobenzodiazepines and their antibody disulfide conjugates
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
BR112017011111A2 (en) 2014-11-25 2017-12-26 Adc Therapeutics Sa pyrrolobenzodiazepine-antibody conjugates
EP3226909A1 (en) 2014-12-03 2017-10-11 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
US10691773B2 (en) 2015-12-30 2020-06-23 General Electric Company Cell processing techniques
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 The drug of the total antibody of multichannel and antibody conjugate quantifies measuring method
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP2019522633A (en) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド PROTAC antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
JP2020517609A (en) 2017-04-18 2020-06-18 メディミューン リミテッド Pyrrolobenzodiazepine complex
KR20190141666A (en) 2017-04-20 2019-12-24 에이디씨 테라퓨틱스 에스에이 Combination Therapy with Anti-AXL Antibody-Drug Conjugates
MX2019015042A (en) 2017-06-14 2020-08-06 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc.
CN111065638B (en) 2017-08-18 2021-04-09 麦迪穆有限责任公司 Pyrrolobenzodiazepine conjugates
BR112020004307A2 (en) 2017-09-20 2020-11-10 Ph Pharma Co., Ltd. tailanestatin analogues
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CN113056287A (en) 2018-10-24 2021-06-29 豪夫迈·罗氏有限公司 Conjugated chemical degradation inducers and methods of use
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854399A (en) * 1991-08-23 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Antibodies specific for human cripto-related polypeptide CR-3
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256643A (en) * 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5633147A (en) * 1994-03-08 1997-05-27 Human Genome Sciences, Inc. Transforming growth factor αH1
US6270777B1 (en) * 1996-12-20 2001-08-07 University Technologies International Inc. Conserved metalloprotease epitopes
US5834399A (en) * 1997-12-22 1998-11-10 Eastman Kodak Company Subbing layer for dye-donor element used in thermal dye transfer
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6387888B1 (en) * 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US6537552B1 (en) * 1999-10-19 2003-03-25 Iowa State University Research Foundation Vaccine adjuvant
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
GB0219776D0 (en) * 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854399A (en) * 1991-08-23 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Antibodies specific for human cripto-related polypeptide CR-3
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BALDASSARRE G ET AL: "TRANSFECTION WITH A CRIPTO ANTI-SENSE PLASMID SUPPRESSES ENDOGENOUS CRIPTO EXPRESSION AND INHIBITS TRANSFORMATION IN A HUMAN EMBRYONAL CARCINOMA CELL LINE", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 4, no. 66, 16 May 1996 (1996-05-16), pages 538 - 543, XP008006513, ISSN: 0020-7136 *

Also Published As

Publication number Publication date
HUP0302824A2 (en) 2005-05-30
GB0020953D0 (en) 2000-10-11
NZ524344A (en) 2004-07-30
US20040138112A1 (en) 2004-07-15
AU2001295498A1 (en) 2002-03-04
ZA200301436B (en) 2004-05-21
WO2002016413A2 (en) 2002-02-28
CZ2003537A3 (en) 2003-09-17
WO2002016413A8 (en) 2003-02-06
CA2420087A1 (en) 2002-02-28
US20040054142A1 (en) 2004-03-18
BR0113491A (en) 2003-06-24
NO20030823D0 (en) 2003-02-21
KR20030045041A (en) 2003-06-09
EP1311678A2 (en) 2003-05-21
CN1471579A (en) 2004-01-28
NO20030823L (en) 2003-04-23
JP2004506441A (en) 2004-03-04
IL154533A0 (en) 2003-09-17
AR032173A1 (en) 2003-10-29
PL363005A1 (en) 2004-11-15
MXPA03001634A (en) 2004-09-10
US7439320B2 (en) 2008-10-21

Similar Documents

Publication Publication Date Title
WO2002016413A8 (en) Cripto tumour polypeptide
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002074156A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001092581A8 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002004514A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002089747A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2004052276A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001051633A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001073032A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002012328A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2002074237A8 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2006031363A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2002058534A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003037267A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002012280A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2002039885A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2005051990A3 (en) Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer
WO2002000174A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003086175A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 2420087

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 154533

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003/01436

Country of ref document: ZA

Ref document number: 524344

Country of ref document: NZ

Ref document number: 200301436

Country of ref document: ZA

Ref document number: 1-2003-500058

Country of ref document: PH

Ref document number: 2002521508

Country of ref document: JP

Ref document number: 224/KOLNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/001634

Country of ref document: MX

Ref document number: PV2003-537

Country of ref document: CZ

Ref document number: 2001295498

Country of ref document: AU

Ref document number: 1020037002701

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 03016548

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2001976131

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018177336

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001976131

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037002701

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10362597

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2003-537

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 524344

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 524344

Country of ref document: NZ

WWR Wipo information: refused in national office

Ref document number: PV2003-537

Country of ref document: CZ